Kaneka Medical America (KMA) - LIPOSORBER’s Post

The LIPOSORBER team will be in Philadelphia on Nov 2-5 for ASN's Kidney Week Annual Meeting. Make sure to stop by our booth (506) to learn about how treatment with LIPOSORBER has enabled nearly 50% of steroid-resistant primary FSGS patients to attain complete or partial remission.* Ref: Muso, Eri et al. “Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.” Clinical and experimental nephrology vol. 19,3 (2015): 379-86. doi:10.1007/s10157-014-0996-8. *Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years. Based on study that took place over two (2) years. #ASN2023 #kidneywk

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics